keyword
MENU ▼
Read by QxMD icon Read
search

Pemetrexed

keyword
https://www.readbyqxmd.com/read/28088782/pde5-inhibitors-enhance-the-lethality-of-pemetrexed-sorafenib
#1
Laurence Booth, Jane L Roberts, Andrew Poklepovic, Paul Dent
The combination of pemetrexed and sorafenib has significant clinical activity against a wide variety of tumor types in patients and the present studies were performed to determine whether sildenafil enhances the killing potential of [pemetrexed + sorafenib]. In multiple genetically diverse lung cancer cell lines, sildenafil enhanced the lethality of [pemetrexed + sorafenib]. The three-drug combination reduced the activities of AKT, mTOR and STAT transcription factors; increased the activities of eIF2α and ULK-1; lowered the expression of MCL-1, BCL-XL, thioredoxin and SOD2; and increased the expression of Beclin1...
January 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28075559/one-component-supramolecular-filament-hydrogels-as-theranostic-label-free-magnetic-resonance-imaging-agents
#2
Lye Lin Lock, Yuguo Li, Xinpei Mao, Hanwei Chen, Verena Staedtke, Renyuan Bai, Wang Ma, Ran Lin, Yi Li, Guanshu Liu, Honggang Cui
Gadolinium (Gd)-based compounds and materials are the most commonly used magnetic resonance imaging (MRI) contrast agents in the clinic; however, safety concerns associated with their toxicities in the free ionic form have promoted the development of new generations of metal-free contrast agents. Here we report a supramolecular strategy to convert an FDA-approved anticancer drug, Pemetrexed (Pem), to a molecular hydrogelator with inherent chemical exchange saturation transfer (CEST) MRI signals. The rationally designed drug-peptide conjugate can spontaneously associate into filamentous assemblies under physiological conditions and consequently form theranostic supramolecular hydrogels for injectable delivery...
January 11, 2017: ACS Nano
https://www.readbyqxmd.com/read/28073680/rationale-and-design-of-pemvitastart-an-open-label-randomized-trial-comparing-simultaneous-versus-standard-initiation-of-vitamin-b12-and-folate-supplementation-in-nonsquamous-non-small-cell-lung-cancer-patients-undergoing-first-line-pemetrexed-based-chemotherapy
#3
Milind Baldi, Digambar Behera, Jyotdeep Kaur, Rakesh Kapoor, Navneet Singh
Pemetrexed is the preferred chemotherapeutic drug for nonsquamous, non-small-cell lung cancer patients whenever the predictive molecular biomarkers for targeted therapy have either not been assessed or are absent. As per manufacturers' instructions, supplementation with folic acid (FA; folate) at a dose of 350 to 1000 μg daily should be started seven days before the first dose of pemetrexed-based chemotherapy and continued during therapy and for 21 days after therapy cessation. Vitamin B12 injections (1000 μg intramuscularly) should also be started one week before the first dose of chemotherapy...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28066120/eyelid-and-feet-edema-induced-by-pemetrexed
#4
Sarrah Kastalli, Ons Charfi, Rym Sahnoun, Ghozlane Lakhoua
Pemetrexed is an anti-metabolite that targets multiple enzymes in folate pathway. The main toxicities associated with pemetrexed are asthenia, nausea, diarrhea, myelosuppression, and rash. Few cases of pemetrexed induced cutaneous adverse event have been reported, mainly periorbital-facial edema and edema of the limbs. We report a case of pemetrexed-induced edema of the eyelid and feet in a patient with adenocarcinoma of the lung.
November 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/28063799/phase-ii-trial-of-dose-dense-pemetrexed-gemcitabine-and-bevacizumab-in-patients-with-advanced-non-small-cell-lung-cancer
#5
Bryan J Schneider, Gregory P Kalemkerian, Shirish M Gadgeel, Manuel Valdivieso, Deborah M Hackstock, Wei Chen, Lance K Heilbrun, John C Ruckdeschel, Antoinette J Wozniak
INTRODUCTION: Platinum-based chemotherapy is standard for untreated, advanced non-small-cell lung cancer (NSCLC). We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10 mg/kg), given every 14 days in patients with untreated, advanced NSCLC...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28058100/non-mucinous-lepidic-predominant-adenocarcinoma-presenting-with-extensive-aerogenous-spread
#6
Yusuke Takanashi, Shogo Tajima, Masaru Tsukui, Kazuya Shinmura, Takamitsu Hayakawa, Tsuyoshi Takahashi, Hiroshi Neyatani, Kazuhito Funai
An extremely rare case of non-mucinous lepidic-predominant invasive adenocarcinoma (LPA) showing extensive aerogenous spread with a pneumonic presentation is reported. A 73-year-old woman was referred to our hospital because of an infiltrative shadow on chest xray. Chest computed tomography revealed extensive ground glass opacities in the right lower lobe, which was accompanied by infiltrative shadow with a pneumonic presentation. Invasive mucinous adenocarcinoma was presumed, and a partial resection of the right lower lobe was done...
November 17, 2016: Rare Tumors
https://www.readbyqxmd.com/read/28045649/cost-effectiveness-of-pemetrexed-in-combination-with-cisplatin-as-first-line-treatment-for-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-in-spain
#7
Jonathan González García, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Cristina Valcárcel Nazco, Jose Norberto Batista López, Juana Oramas Rodríguez
INTRODUCTION: Lung cancer is the third most frequent neoplastic tumour in Spain, with around 27 000 new cases diagnosed per year; 80-95% of these are non-small-cell cancer (NSCLC), and the majority of cases are diagnosed in advanced stages of the disease, and for this reason it is one of the oncologic conditions with higher mortality rates (21.4% mean survival at 5 years). The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev)...
January 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28045621/antineoplastic-treatment-of-advanced-stage-non-small-cell-lung-cancer-treatment-survival-and-spending-2000-to-2011
#8
Cathy J Bradley, K Robin Yabroff, Angela B Mariotto, Christopher Zeruto, Quyen Tran, Joan L Warren
Purpose Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163). We estimated the adjusted percentage of patients who received each agent, days while on treatment, survival, and spending in the 12 months after diagnosis...
January 3, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28036283/cost-effectiveness-of-gefitinib-icotinib-and-pemetrexed-based-chemotherapy-as-first-line-treatments-for-advanced-non-small-cell-lung-cancer-in-china
#9
Shun Lu, Ming Ye, Lieming Ding, Fenlai Tan, Jie Fu, Bin Wu
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR mutation, but the economic impact of this practice is unclear, especially in a health resource-limited setting. A decision-analytic model was developed to simulate 21-day patient transitions in a 10-year time horizon. The health and economic outcomes of four first-line strategies (pemetrexed plus cisplatin [PC] alone, PC followed by maintenance with pemetrexed, or initial treatment with gefitinib or icotinib) among patients harboring EGFR mutations were estimated and assessed via indirect comparisons...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/28034896/role-of-cps1-in-cell-growth-metabolism-and-prognosis-in-lkb1-inactivated-lung-adenocarcinoma
#10
Müge Çeliktaş, Ichidai Tanaka, Satyendra Chandra Tripathi, Johannes F Fahrmann, Clemente Aguilar-Bonavides, Pamela Villalobos, Oliver Delgado, Dilsher Dhillon, Jennifer B Dennison, Edwin J Ostrin, Hong Wang, Carmen Behrens, Kim-Anh Do, Adi F Gazdar, Samir M Hanash, Ayumu Taguchi
BACKGROUND: Liver kinase B1 (LKB1) is a tumor suppressor in lung adenocarcinoma (LADC). We investigated the proteomic profiles of 45 LADC cell lines with and without LKB1 inactivation. Carbamoyl phosphate synthetase 1 (CPS1), the first rate-limiting mitochondrial enzyme in the urea cycle, was distinctively overexpressed in LKB1-inactivated LADC cell lines. We therefore assessed the role of CPS1 and its clinical relevance in LKB1-inactivated LADC. METHODS: Mass spectrometric profiling of proteome and metabolome and function of CPS1 were analyzed in LADC cell lines...
March 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28032090/efficacy-and-toxicity-profile-of-maintenance-pemetrexed-in-patients-with-stage-iv-adenocarcinoma-lung-in-indian-population
#11
Goyal Pankaj, Batra Ullas, Dinesh Chandra Doval, Jain Parveen, Upadhyay Kumar Amitabh, Prasanta Kumar Dash, Jain Akhil, Mohit Agarwal, Bajaj Rajat
CONTEXT: Lung cancer has been the most common cancer in the world for several decades. Pemetrexed is recommended as an option for the maintenance treatment in metastatic adenocarcinoma lung, if disease has not progressed immediately following platinum-based chemotherapy. AIMS: To study efficacy and toxicity profile of pemetrexed as a maintenance chemotherapeutic agent in patients with stage IV adenocarcinoma lung, not progressing after first line chemotherapy. Settings and Design: This was an observational, prospective...
October 2016: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28031827/pemetrexed-for-epithelioid-haemangioendothelioma-of-the-pleura
#12
Shingo Kanemura, Kozo Kuribayashi, Yumiko Moriya, Shigeki Shimizu, Tohru Tsujimura, Takashi Nakano
A 31-year-old woman presented with a 2-month history of dull left back pain. Chest roentgenography revealed pleural thickening in the left lung apex, whereas chest computed tomography showed a left pleural effusion with diffuse pleural thickening. Based on these findings, malignant mesothelioma was suspected. Video-assisted thoracoscopic pleural biopsy was performed, and subsequent staining of the specimen revealed negative results for anti-cytokeratin antibodies and positive results for vascular endothelial immunohistochemical markers...
November 2016: Respirology Case Reports
https://www.readbyqxmd.com/read/28027772/metabolic-response-assessment-with-18f-fdg-pet-ct-is-superior-to-modified-recist-for-the-evaluation-of-response-to-platinum-based-doublet-chemotherapy-in-malignant-pleural-mesothelioma
#13
Shingo Kanemura, Kozo Kuribayashi, Norihiko Funaguchi, Eisuke Shibata, Koji Mikami, Hiroshi Doi, Kazuhiro Kitajima, Seiki Hasegawa, Takashi Nakano
PURPOSE: Efficient monitoring of tumor responsiveness to chemotherapy is essential to mitigate high mortality risks and cytotoxic effects of chemotherapeutics. However, there is no consensus on the most suitable diagnostic technique/parameters for assessing response to chemotherapy in malignant pleural mesothelioma (MPM). We compared the tumor responsiveness of MPM patients as assessed using modified RECIST (mRECIST) criteria and integrated 18F-FDG-PET/CT. METHODS: Histologically confirmed MPM patients (N=82) who were treated with three cycles of cisplatin and pemetrexed, or carboplatin and pemetrexed, were included...
January 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28027106/systemic-treatment-for-thymic-malignancies
#14
Nicolas Girard, Claire Merveilleux du Vignaux
PURPOSE OF REVIEW: The management of thymic epithelial tumors is a paradigm of multidisciplinary collaboration. Chemotherapy may be administered as part of curative-intent sequential strategy integrating subsequent surgery or radiotherapy, or as an exclusive treatment if local treatment is not achievable. Recurrences of thymic epithelial tumors should be managed according to the same strategy as newly diagnosed tumors. RECENT FINDINGS: More options have become available for advanced, refractory, and recurrent thymic epithelial tumors, which include cytotoxic agents such as carboplatin-paclitaxel, pemetrexed, and oral etoposide...
December 23, 2016: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28024927/utilization-patterns-and-trends-in-epidermal-growth-factor-receptor-egfr-mutation-testing-among-patients-with-newly-diagnosed-metastatic-lung-cancer
#15
Chan Shen, Kenneth L Kehl, Bo Zhao, George R Simon, Shouhao Zhou, Sharon H Giordano
INTRODUCTION: Epidermal growth factor receptor (EGFR)-targeted therapy significantly improves outcomes among patients with non-small-cell lung cancer (NSCLC) whose tumors harbor sensitizing mutations. Patterns of EGFR testing have not been well-documented. The objective of this population-based study is to assess the testing pattern on a national scale. PATIENTS AND METHODS: Using MarketScan 2012 to 2014 data, we identified 5842 patients newly diagnosed with metastatic lung cancer from January 2013 to June 2014 and assessed their EGFR mutation testing pattern in the 6 months after diagnosis...
November 11, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27997007/-new-perspectives-in-second-line-treatment-in-non-squamous-non-small-cell-lung-cancer
#16
Francesco Grossi
The treatment options for patients with non-squamous non-small cell lung cancer (NSCLC) in second-line have been limited for a long time. Docetaxel, pemetrexed and erlotinib are the standard second-line treatment. Docetaxel is frequently used although it is associated with an unfavorable safety profile. Recently, the results from the trial CheckMate 057 with nivolumab, an anti-PD-1 inhibitor, has increased the therapeutic options for patients with non-squamous NSCLC in the second-line setting. The results of this randomized phase III trial comparing nivolumab vs docetaxel have deeply changed our current clinical practice...
December 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27993482/bevacizumab-plus-pemetrexed-versus-pemetrexed-alone-as-maintenance-therapy-for-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-update-from-the-swiss-group-for-clinical-cancer-research-sakk-19-09-trial
#17
Oliver Gautschi, Sacha I Rothschild, Qiyu Li, Klazien Matter-Walstra, Alfred Zippelius, Daniel C Betticher, Martin Früh, Rolf A Stahel, Richard Cathomas, Daniel Rauch, Miklos Pless, Solange Peters, Patrizia Froesch, Thilo Zander, Martina Schneider, Christine Biaggi, Nicolas Mach, Adrian F Ochsenbein
BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non-small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone. PATIENTS AND METHODS: We conducted a nonrandomized phase II trial with 2 sequential cohorts. In the first cohort, 77 patients were treated with 4 cycles of cisplatin, bevacizumab, and pemetrexed every 3 weeks, followed by bevacizumab plus pemetrexed maintenance until progression...
November 23, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27987591/nintedanib-plus-pemetrexed-versus-placebo-plus-pemetrexed-in-patients-with-relapsed-or-refractory-advanced-non-small-cell-lung-cancer-lume-lung-2-a-randomized-double-blind-phase-iii-trial
#18
Nasser H Hanna, Rolf Kaiser, Richard N Sullivan, Osvaldo Rudy Aren, Myung-Ju Ahn, Beatrice Tiangco, Isabelle Voccia, Joachim von Pawel, Vladimir Kovcin, Jason Agulnik, Birgit Gaschler-Markefski, José Barrueco, Patricia Sikken, Charles Schloss, Joo-Hang Kim
OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27987582/a-folylpoly-%C3%AE-glutamate-synthase-single-nucleotide-polymorphism-associated-with-response-to-pemetrexed-treatment-combined-with-platinum-for-non-small-cell-lung-cancer
#19
Satoshi Fukuda, Tetsuya Oguri, Eiji Kunii, Kazuki Sone, Takehiro Uemura, Osamu Takakuwa, Ken Maeno, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi
OBJECTIVES: In this study, we investigated whether single nucleotide polymorphisms (SNPs) in folylpoly-γ-glutamate synthase (FPGS), which catalyzes the polyglutamation of pemetrexed (PEM), is related to FPGS expression and the response to PEM in non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We first examined FPGS protein expressions according to FPGS SNPs genotype groups in 15 lung adenocarcinoma cell lines. Next, 101 non-squamous NSCLC patients treated with PEM and platinum drugs were classified into FPGS SNP genotype groups to investigate the relation between FPGS SNP genotypes and treatment outcome...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27973147/economic-burden-of-gefitinib-versus-pemetrexed-for-insured-patients-with-lung-cancer-in-urban-xinjiang-province-china-a-real-world-research
#20
W Mao, W Chen
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
8879
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"